JP2016074727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016074727A5 JP2016074727A5 JP2015242089A JP2015242089A JP2016074727A5 JP 2016074727 A5 JP2016074727 A5 JP 2016074727A5 JP 2015242089 A JP2015242089 A JP 2015242089A JP 2015242089 A JP2015242089 A JP 2015242089A JP 2016074727 A5 JP2016074727 A5 JP 2016074727A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- hiv
- viral vector
- vaccine according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24352209P | 2009-09-17 | 2009-09-17 | |
| US61/243,522 | 2009-09-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529911A Division JP2013505256A (ja) | 2009-09-17 | 2010-09-17 | Ｈｉｖ用の免疫学的組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017206895A Division JP6619788B2 (ja) | 2009-09-17 | 2017-10-26 | Ｈｉｖ用の免疫学的組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016074727A JP2016074727A (ja) | 2016-05-12 |
| JP2016074727A5 true JP2016074727A5 (https=) | 2016-09-15 |
Family
ID=43086913
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529911A Pending JP2013505256A (ja) | 2009-09-17 | 2010-09-17 | Ｈｉｖ用の免疫学的組成物 |
| JP2015242089A Pending JP2016074727A (ja) | 2009-09-17 | 2015-12-11 | Ｈｉｖ用の免疫学的組成物 |
| JP2017206895A Expired - Fee Related JP6619788B2 (ja) | 2009-09-17 | 2017-10-26 | Ｈｉｖ用の免疫学的組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529911A Pending JP2013505256A (ja) | 2009-09-17 | 2010-09-17 | Ｈｉｖ用の免疫学的組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017206895A Expired - Fee Related JP6619788B2 (ja) | 2009-09-17 | 2017-10-26 | Ｈｉｖ用の免疫学的組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120308593A1 (https=) |
| EP (2) | EP2477651A1 (https=) |
| JP (3) | JP2013505256A (https=) |
| AU (1) | AU2010295497B2 (https=) |
| CA (1) | CA2774154A1 (https=) |
| WO (1) | WO2011035082A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012279018B2 (en) | 2011-07-05 | 2017-06-08 | Children's Medical Center Corporation | N-terminal deleted GP120 immunogens |
| WO2013052095A2 (en) | 2011-10-03 | 2013-04-11 | Duke University | Vaccine |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| CA2884859C (en) | 2012-09-12 | 2024-06-18 | Duke University | Hiv-1 antibody evolution immunogens |
| WO2014172335A1 (en) | 2013-04-15 | 2014-10-23 | Duke University | Polyvalent hiv-1 immunogen |
| US10208358B2 (en) * | 2014-04-14 | 2019-02-19 | Indiana University Reasearch and Technology Corporation | Generalizable assay for virus capsid assembly |
| TWI810456B (zh) | 2019-05-22 | 2023-08-01 | 美商基利科學股份有限公司 | Tlr7調節化合物及hiv疫苗之組合 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001054701A1 (en) * | 2000-01-31 | 2001-08-02 | Aventis Pasteur, S.A. | Vaccination of hiv infected persons following highly active antiretroviral therapy |
| US7094408B2 (en) * | 2000-04-28 | 2006-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Immunogenicity using a combination of DNA and vaccinia virus vector vaccines |
-
2010
- 2010-09-17 CA CA2774154A patent/CA2774154A1/en not_active Abandoned
- 2010-09-17 AU AU2010295497A patent/AU2010295497B2/en not_active Ceased
- 2010-09-17 EP EP10755306A patent/EP2477651A1/en not_active Withdrawn
- 2010-09-17 JP JP2012529911A patent/JP2013505256A/ja active Pending
- 2010-09-17 WO PCT/US2010/049206 patent/WO2011035082A1/en not_active Ceased
- 2010-09-17 US US13/395,666 patent/US20120308593A1/en not_active Abandoned
- 2010-09-17 EP EP15175346.4A patent/EP2987500A1/en not_active Withdrawn
-
2015
- 2015-12-11 JP JP2015242089A patent/JP2016074727A/ja active Pending
-
2017
- 2017-10-26 JP JP2017206895A patent/JP6619788B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016074727A5 (https=) | ||
| JP2019526580A5 (https=) | ||
| Gray et al. | Approaches to preventative and therapeutic HIV vaccines | |
| Kardani et al. | Prime-boost vaccine strategy against viral infections: Mechanisms and benefits | |
| Rollier et al. | Viral vectors as vaccine platforms: deployment in sight | |
| García-Arriaza et al. | Enhancing poxvirus vectors vaccine immunogenicity | |
| JP6462861B2 (ja) | フィロウイルス感染に対する防御免疫の誘導を目的とする方法及び組成物 | |
| JP2019123734A (ja) | 免疫応答の増進を目的とする方法及び組成物 | |
| CA2725383C (en) | Smallpox dna vaccine and the antigens therein that elicit an immune response | |
| Johnson et al. | Nonreplicating vectors in HIV vaccines | |
| JP2018148890A5 (https=) | ||
| Paris et al. | Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1 | |
| CN112121160A (zh) | 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物 | |
| WO2005028634A2 (en) | Improved mva vaccines | |
| JP2016510989A5 (https=) | ||
| Lema et al. | HIV vaccines: a brief overview | |
| JP2010523138A5 (https=) | ||
| RU2015115785A (ru) | Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака | |
| Herath et al. | Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag–pol–nef antigen | |
| Kulkarni et al. | DNA vaccination by intradermal electroporation induces long‐lasting immune responses in rhesus macaques | |
| Meseda et al. | Percutaneous vaccination as an effective method of delivery of MVA and MVA-vectored vaccines | |
| Radaelli et al. | Different immunogens and prime-boost vaccination strategies affect the efficacy of recombinant candidate vaccines against pathogenic orthopoxviruses | |
| genannt Bonsmann et al. | The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses | |
| Zhang et al. | Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system | |
| Liu et al. | Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine |